Doctor smiling
Doctors analyzing x-Ray

Redefining the Potential of

Dentritic
Cell Vaccines

Developed at the Texas Medical Center, DOC1021 represents a novel approach to fighting cancer that harnesses the body’s natural anti-viral immune response.

At the core of DOC1021 is Diakonos’ proprietary “double-loading” technique. This patented process tricks the body into perceiving cancer cells as virally infected cells, mirroring the natural detection and elimination process for viral infections.
Learn More
Hexagons

Powered by a

Groundbreaking
Discovery on the
Immune System

DOC1021 is based on a discovery on how dendritic cells are able to detect and respond to viral threats. Based on Diakonos’ research, it is now known that dendritic cells compare antigens presented on MHC Class 1 and 2.

When identical antigens are detected on both MHC Class 1 and 2, dendritic cells mobilize formidable CD8 CD161 T cells to destroy what the immune system believes are infected cells throughout the body.
Learn More About Our Science

Diakonos Oncology

News & Media

Ian H. Bellayr, Ph.D., Joins as Chief Regulatory Officer

Ian H. Bellayr, Ph.D., Joins as Chief Regulatory Officer

HOUSTON, (November 20, 2023) —Diakonos Oncology Corporation (“Diakonos”), a clinical-stage immuno-oncology company, announced today that Ian H. Bellayr, Ph.D., a regulatory expert with the U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH), has joined the company as its Chief Regulatory Officer. “Dr. Bellayr’s regulatory expertise arrives at a crucial time for […]

Read More
Awarded TLSF Top 10 Most Promising Life Science Companies

Awarded TLSF Top 10 Most Promising Life Science Companies

The Diakonos Oncology team is excited to announce that the company has been selected as one of the Top 10 Most Promising Life Science Companies at the 2023 Texas Life Science Forum. This prestigious event, hosted annually in November by Rice University and BIOHouston, brings together the most innovative minds in the life science sector. […]

Read More
Diakonos Awarded FDA Fast Track Designation

Diakonos Awarded FDA Fast Track Designation

HOUSTON, (October XX, 2023) —Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021. The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients […]

Read More

Clinical Trials

Underway

Discover our treatment centers and find out which one is best for you.

Baylor College of MedicinePhase 1, NCT04157127

Pancreatic Adenocarcinoma

Baylor College of MedicinePhase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.
MD Anderson Cooper, UT Health Science Center<br /> Phase 1, NCT04552886

Glioblastoma

MD Anderson Cooper, UT Health Science Center
Phase 1, NCT04552886

Conducted in partnership with the MD Anderson Cooper Hospital, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Glioblastoma (GBM) after undergoing neurosurgical tumor resection, and in whom a neuropathological diagnosis has been established.
MD Anderson<br /> Phase 1, Pending

Sarcoma

MD Anderson
Phase 1, Pending

Conducted in partnership with the MD Anderson, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Sarcoma after undergoing Standard of Care.